Psoriasis is a chronic disease that requires long-term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)-23. This article reviews published data on the safety of these IL-23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo-and active-controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk-benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL-23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL-23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long-term extension studies and patient registries will further establish the safety profile of IL-23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice.
Introduction
Psoriasis is a chronic T-cell-mediated inflammatory skin disease, estimated to affect more than 100 million individuals worldwide, of whom approximately 20% have moderate to severe disease. changed the disease management paradigm. Multiple biologic therapies are now available or in late stages of development (Table 1) , targeting different inflammatory cytokines (Fig. 1 ). These include tumour necrosis factor (TNF) antagonists, IL-17 inhibitors, an IL-12/23p40 inhibitor and monoclonal antibodies that target the p19 subunit that is specific to IL-23.
Psoriasis is a chronic disease that often requires ongoing treatment. Consequently, the long-term safety and tolerability of any treatment are critical to effective prescribing. Early biologic agents for the treatment of psoriasis typically induced non-specific immunosuppression, including agents targeting T-cell activation and migration (efalizumab and alefacept, both of which have now been withdrawn) and anti-TNF agents that target a key cytokine involved in most inflammatory and infectious processes in the body. 4 TNF antagonists have been associated with increased risk of serious bacterial, viral and fungal infections in patients with psoriasis, including active tuberculosis and reactivation of latent tuberculosis infection. [5] [6] [7] [8] [9] The data on malignancy risk with long-term exposure to TNF antagonists are conflicting, with some studies and recent registry data suggesting a potential increased risk. [5] [6] [7] [8] 10 Rare cases of new onset or exacerbation of demyelinating disorders have also been reported during treatment with TNF antagonists. [5] [6] [7] [8] As understanding of psoriasis disease mechanisms has advanced, more targeted therapies have become available with the potential for improved safety and tolerability. Three agents targeting the IL-17 cytokine pathway are available; secukinumab and ixekizumab are specific to IL-17A, whereas brodalumab is 
Safety data from clinical trials
Results of phase 1 and 2 studies showed favourable safety and tolerability profiles in adult patients with moderate to severe psoriasis for guselkumab, [33] [34] [35] [36] tildrakizumab 37, 38 and risankizumab. 39, 40 These findings were confirmed by results of randomized, controlled phase 3 clinical trials (Table 2) , with no major ADA, adalimumab; AE, adverse event; biw, twice per week; ETN, etanercept; GUS, guselkumab; IL, interleukin; MACE, major cardiovascular adverse event;
N, number of patients included; NR, not reported; PBO, placebo; RIS, risankizumab; SAE, serious adverse event; TIL, tildrakizumab; UST ustekinumab; q2w, every 2 weeks; q8w, every 8 weeks; q12w, every 12 weeks; qw, every week; Wk, week.
safety concerns identified for any available IL-23p19 inhibitor. [41] [42] [43] [44] [45] Key exclusion criteria for these studies typically included any malignancy within the past 5 years (except nonmelanoma skin cancer), active or untreated latent tuberculosis and testing positive for human immunodeficiency, hepatitis B virus or hepatitis C virus infection. Women could not be pregnant, and those of child-bearing potential had to practice abstinence or use medically accepted contraception methods.
No head-to-head studies have compared the different IL23p19 inhibitors, and care must be taken when comparing data among studies because of differing study designs, patient populations and study lengths.
Guselkumab
Results of three pivotal phase 3 trials of guselkumab in adult patients with moderate to severe psoriasis have been reported: VOYAGE 1 (NCT02207231), VOYAGE 2 (NCT02207244) and NAVIGATE (NCT02203032). [41] [42] [43] In VOYAGE 1 (n = 837) and VOYAGE 2 (n = 922), patients were randomized to guselkumab (100 mg at Weeks 0 and 4, then every 8 weeks), adalimumab (80 mg at Week 0, 40 mg at Week 1, then 40 mg every 2 weeks) or placebo (Weeks 0, 4 and 12, then guselkumab at Weeks 16 and 20, then every 8 weeks). 41, 42 Rates of AEs, serious AEs (SAEs) and infections were comparable across groups in both studies over the 48 weeks of follow-up ( Table 2 ). The most common AEs in all groups were nasopharyngitis, headache and upper respiratory infection, and few patients (≤4%) discontinued treatment owing to AEs. Incidence rates of serious infections and candidiasis were low and comparable between groups in both studies, and no AEs of inflammatory bowel disease were reported. Rates of malignancies and MACE were low in all groups (<1% over the study period). A single suicide attempt was reported in a patient taking adalimumab in VOYAGE 1.
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In VOYAGE 2, greater improvements in anxiety and depression scores were seen in patients treated with guselkumab than in those who received adalimumab or placebo. 46 The NAVIGATE trial assessed guselkumab in adult patients with an inadequate response to ustekinumab. 43 Guselkumab was also well tolerated in a 52-week, phase 3, placebo-controlled study in 192 adult Japanese patients with moderate to severe plaque psoriasis (NCT02325219), with no safety concerns identified in this population. 47 Again, nasopharyngitis was the most commonly reported AE in all groups.
Tildrakizumab
Week 28 data from two phase 3 trials of tildrakizumab have been reported: reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754). 44 A total of 772 adult patients were randomized (2 : 2 : 1) to tildrakizumab 200 mg, tildrakizumab 100 mg or placebo in reSURFACE 1; in reSURFACE 2, 1090 patients were randomized (2 : 2 : 2 : 1) to tildrakizumab 200 mg, tildrakizumab 100 mg, etanercept or placebo. In both studies, AEs and SAEs were reported at similar rates across all treatment groups, and discontinuations due to AEs were infrequent ( Table 2) . Nasopharyngitis was the most common AE in both studies. Candida skin infections and oral candidiasis were infrequent, and no cases of new onset or worsening of inflammatory bowel disease were reported. Incidences of serious infections, malignancies and MACE were low and similar across groups (≤1% in any group). One patient died in reSURFACE 2 in the tildrakizumab 100-mg group; the patient had alcoholic cardiomyopathy and steatohepatitis, and adjudication was unable to determine the cause of death. These results were confirmed by a pooled analysis of data from three randomized controlled trials [a phase 2b study (NCT01225731) and reSURFACE 1 and 2], which showed that long-term treatment (>64 weeks) with tildrakizumab was well tolerated in patients with moderate to severe psoriasis. 48 Data were included for 2081 adult patients treated with tildrakizumab 200 mg, tildrakizumab 100 mg, etanercept or placebo. Over the full-trial period, exposure-adjusted rates of AEs and SAEs with tildrakizumab were lower than or comparable with etanercept and placebo ( reported. One suicide attempt was reported in a patient receiving tildrakizumab 200 mg and antipsychotic therapy for a known history of schizophrenia; this was considered unrelated to treatment by the investigator.
Risankizumab
Two 52-week, phase 3 trials of risankizumab vs. ustekinumab have been reported, with no unexpected safety findings: UltIMMa-1 (NCT02684370) and UltIMMa-2 (NCT02684357). 45 In both studies, adult patients were randomized (3 : 1 : 1) to receive risankizumab 150 mg, ustekinumab 45 mg or 90 mg or placebo (506 in UltIMMa-1 and 491 in UltIMMa-2). Rates of AEs were similar across all groups during both the placebo-controlled period (Weeks 0-16) and long-term follow-up (Weeks 16-52) ( Table 2) . Rates of discontinuation due to AEs were low and similar across all groups during both study periods. In both studies, infections were more frequently reported in patients receiving risankizumab or ustekinumab compared with placebo, and the most common AE was upper respiratory tract infection. Rates of serious infections were low (≤1% for risankizumab and placebo, ≤3% for ustekinumab). No clinically relevant opportunistic infections were reported, and there were no reports of Candida infections or new onset/worsening of inflammatory bowel disease. Incidences of malignancies and MACE were low (all ≤1%). No demyelinating disorders or suicide were reported. In UltIMMa-2, one patient died in the risankizumab group of an unknown cause.
Other safety data
Data from head-to-head comparator trials of IL-23p19 inhibitors vs. IL-17 or IL-12/23p40 inhibitors are starting to emerge. Risankizumab was compared with ustekinumab in a 48-week phase 2 trial (NCT02054481) 40 and in the phase 3 UltIMMAa-1
and UltIMMAa-2 studies, in which broadly similar safety profiles were reported for both treatments. 45 Ustekinumab was compared with guselkumab in the NAVIGATE trial (described above), 43 in which more AEs occurred in the guselkumab group (64%) than the ustekinumab group (56%). Further studies comparing treatments are ongoing or awaiting publication, including guselkumab vs. secukinumab (phase 2, NCT03553823; phase 3, NCT03090100) and vs. ixekizumab (phase 4, NCT03573323) and risankizumab vs. secukinumab (phase 3, NCT03478787). In addition, three recent meta-analyses have assessed the safety of IL-23p19 inhibitors compared with other classes of biologic agents used for the treatment of psoriasis. [50] [51] [52] To avoid risk of confounding, these meta-analyses exclusively used data from the placebo-controlled treatment periods of randomized controlled trials (typically 12-16 weeks). Sbidian and colleagues 50 conducted a network meta-analysis of 109 studies to compare the efficacy and safety of conventional systemic agents, small molecules and biologic agents in 39 882 patients with moderate to severe psoriasis. They found no significant differences between tildrakizumab, guselkumab, ustekinumab, etanercept, infliximab, adalimumab and certolizumab verses placebo in terms of the risk of SAEs, serious infections, malignancies or MACE. 50 The second meta-analysis assessed the efficacy and safety of IL-23p19, IL-12/23p40 and IL-17 inhibitors in moderate to 11 -13 The third meta-analysis was undertaken to compare the safety of biologics targeting IL-17 and IL-23 in the treatment of moderate to severe plaque psoriasis and found anti-IL-23 agents were associated with a lower risk of AEs. 52 Data from the placebo- 
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Unmet needs
Real-world data concerning the safety of IL-23p19 inhibitors in routine practice settings are not yet available. Registry data are important for identifying safety signals arising during wider and longer term clinical use, which may not have been recognized during clinical trials. Registry data may also provide reassurance regarding real-world safety and tolerability by failing to confirm spurious signals occasionally seen in trials. For example, although three possible MACE were recorded in a phase 2 ustekinumab study, 58 no further signal was identified in long-term follow-up or registry data. [24] [25] [26] Although a significant proportion of patients with psoriasis are women of child-bearing potential, only limited data are available concerning the safety of biologic agents during pregnancy. No reports of pregnancies during treatment with an IL-23p19 inhibitor in clinical trials have been published, although preliminary data from 13 pregnancies during treatment with tildrakizumab reported no anomalies. 59 Similarly, data from pregnant women with psoriasis treated with ustekinumab have not identified any safety concerns. 60, 61 It is generally recommended that live vaccines should not be given to infants exposed to biologic agents in utero for at least 6 months after birth, because of a theoretical concern about the response to vaccination. Although there are no published data following exposure to IL-23p19 inhibitors, the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes (PIANO) registry found use of other biologic therapies by pregnant women with inflammatory bowel disease did not affect infant response to Haemophilus influenzae B or tetanus vaccines. 62 In adult patients, long-term (≥3 years) treatment with ustekinumab was not found to compromise immune response to pneumococcal or tetanus vaccines, but there are no data on vaccine response during treatment with IL-23p19 inhibitors. 63 However, it is recommended that patients receive all age-appropriate immunizations prior to initiating treatment, and patients should not receive live vaccines while on therapy with ustekinumab, guselkumab or tildrakizumab. [64] [65] [66] Biologic therapies are increasingly used for the treatment of moderate to severe psoriasis in children. 67 Data on the safety of IL-23p19 inhibitors in paediatric patients are not yet available, although a study of guselkumab in adolescents is ongoing (PROTOSTAR; NCT03451851). Ustekinumab has been approved for the treatment of moderate to severe plaque psoriasis in adolescents aged 12 years or older; the safety profile is similar to that in adults, with nasopharyngitis the most common AE and no unexpected AEs. 68 
Conclusions
Available data show anti-IL-23p19 agents have an acceptable safety profile in adults with moderate to severe psoriasis. The most commonly reported AEs during treatment with IL-23p19 inhibitors in phase 3 studies were upper respiratory tract infections. Rates of serious infections, malignancies or MACE were extremely low and comparable to those seen with placebo or active comparators. Importantly, few patients discontinued treatment with IL-23p19 inhibitors owing to AEs during clinical trials. Selectively targeting IL-23p19 appears to avoid AEs that have been associated with biologic agents with other mechanisms of action, with no signals for elevated risk of opportunistic infections, tuberculosis, mucocutaneous Candida infections, de novo onset or potential exacerbation of inflammatory bowel disease or demyelinating disorders observed to date. Data from long-term extension studies and patient registries are needed to fully establish the safety profile of these agents for the treatment of moderate to severe psoriasis in routine practice.
